Company Name	Pharmaxis Ltd
Corporate Objective	Research, development and commercialisation of human healthcare products for the treatment and management of chronic diseases
Registered Office	20 Rodborough Road Frenchs Forest NSW 2086 Australia
Other Offices	Europe Pharmaxis Hungarian Representative Office BRAVOS BUSINESS PARK H-2000 Szentendre Kalaszi ut 3 Hungary
Sector	Life Science / Bio-Technology / Pharmaceutical
Internet Homepage Address (URL)	http://www.pharmaxis.com.au
Phone Number	+61 2 9454 7200
Fax Number	+61 2 9451 3622
Email Address	Info@pharmaxis.com.au
Financial Year End	June 30
Board of Directors	Malcolm J McComas (Independent Chairman) (Appointed on 1 May 2012) Gary J Phillips (Chief Executive Officer) (Appointed on 12 March 2013) William L Delaat (Non-Executive Director) Dr Simon HW Buckingham (Non-Executive Director) (Appointed on 25 July 2012) Dr Kathleen M Metters (Non-Executive Director) (Appointed on 7 June 2017) David M McGarvey (Company Secretary)
Company Secretary and Chief Financial Officer	David M McGarvey
Management Team	Gary J Phillips (Chief Executive Officer) (Appointed on 12 March 2013) David M McGarvey (Chief Financial Officer) Brett Charlton (Medical Director) Wolfgang G Jarolimek (Head of Drug Discovery) Kristen Morgan (Alliance Management) (Appointed 25 May 2015)
Investor Relations Contact	David M McGarvey
Principal Banker	HSBC Bank Australia Ltd Westpac Banking Corporation
Auditors	PricewaterhouseCoopers Darling Park Tower 2 201 Sussex Street Sydney NSW 2000 Australia Phone: +61 2 8266 0000 Fax: +61 2 8266 9999
Legal Advisors	PFM Legal Pty Ltd Level 7, 257 Clarence Street Sydney, NSW 2000 Australia
Share Registry	Computershare Investor Services Pty Ltd Level 3, 60 Carrington Street Sydney NSW 2000 Australia Phone: +61 3 9415 4000 (within Australia: 1300 855 080) Fax: +61 3 9473 2500 www.computershare.com.au
ADR Registrar and Transfer Agent	BNY Mellon Shareowner Services 480 Washington Blvd., 27th floor Jersey City, NJ 07310 United States of America Phone within the U.S.: (201) 680-4000 Phone outside the U.S.: +1 201 680 6825
Stock Symbol	ASX Stock Code: PXS OTC: PXSLY
Listing Date	ASX: November 2003
Shares on issue	319m (as of 26 June 2017)
Employee Options	10m (as of 26 June 2017)
Institutional Shareholders	~50% Australia / NZ - Australian Ethical (10%); Allan Gray (8%); Other (1%) US - BVF Partners (19%); Other (2%) UK - Montoya Investments (6%); Other (3%) (as of 26 June 2017)
Substantial Shareholders	- BVF Partners LP: 18.94% 4 April 2017 - Australian Ethical Australian Share Fund: 10.16% 3 April 2017 - Allan Gray Australia: 8.16% 5 April 2017 - Montoya Investments Limited: 6.20% 12 April 2017
Number of Shareholders	Approximately 5,150 holders (as of 4 May 2016)
Shares Traded	- Three months: 35m - Six months: 49m - Twelve months: 84m (as of 26 June 2017)
Cash at bank	$26,499,000 (as of 31 March 2017)
Market Capitalisation	A$80m (as of 26 June 2017)
Drug Discovery	Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO) Inhibitor PXS4728A is currently in a phase 1 clinical trial with positive early results. The drug is targeting the diabetes and liver-related condition Non-Alcoholic Steatohepatitis (NASH) and Chronic Obstructive Pulmonary Disease (COPD). A Lysyl Oxidase Inhibitor (LOXL2) program is also under development for the treatment of fibrotic diseases including pulmonary fibrosis and some cancers.
Approved Products	Aridol: assessment of asthma approved and sold in Europe, Australia and Asia   Bronchitol for cystic fibrosis: an inhaled dry powder for the treatment of cystic fibrosis is marketed in Europe and Australia a clinical trial is underway aiming to secure approval in the United States
ACN	082 811 630
ABN	75 082 811 630